Biosimilars have stopped being a specialty conversation and become a day-to-day operational test. A pharmacist wants to know whether substitution is safe. A payer wants to know whether outcomes match the label. A regulator wants to know whether your story survives cross-examination. The biosimilars market reached $26.5 billion in 2024 and is projected to reach $185.1 billion by 2033, a scale shift that rewards teams who can make clinical proof portable instead of fragile. Dr. Hong Xie, Chief Technology and Medical Officer at Boston Easy Biotech, has built her operating style around that idea, and her role as an editorial board member for IJETCSIT reflects a preference for claims that can be checked line by line. To understand how evidence-first teams are keeping proof intact as categories expand, we turned to Xie.
“A good program is the one that reads clearly under pressure,” says Xie. “If the evidence is hard to follow, the questions will find you. When the record is clean, you can answer fast and move on.” That pressure is rising as biosimilars stack up across categories and care settings. The FDA has approved 76 biosimilars to date, which means more teams are living in the space between scientific comparability and real-world execution. The operational takeaway is blunt. Your submission story cannot depend on the context that only your team remembers.
In her current role, Xie ensures compliance with global regulatory bodies including the FDA and EMA and oversees submissions, translating clinical reality into regulator-ready packages that do not collapse under follow-up questions. She treats every ambiguous sentence as a future delay. Small wording choices become time on the calendar, and time is expensive once external review starts.
Once submissions become routine, the next failure mode is internal: teams drift into “we usually do it this way” instead of “this is the controlled method.” That is how variation sneaks in. Dr. Xie insists on establishing various operating standards and business SOPs, ensuring that the operational procedures are written in a way that allows reviewers to perform accurately, even when in a fatigued state.
At Boston Easy Biotech, she establishes and enforces clinical protocols, safety standards, and GD&T-aligned validation where it applies. Here is the kind of moment she remembers: a review meeting where a draft protocol used the phrase “standard handling.” She stopped the room and asked what that meant at 6 p.m., with a late shipment and a short staff. Silence. Then edits. “If you cannot define the step, you cannot defend it,” states Xie. “Clarity is not paperwork, it is risk control, especially when the day is messy and the staff is thin. If ‘standard handling’ means different things at 6 p.m., then it is not a method, it is a gamble.”
Virtual care has made measurement unavoidable, because online care happens at volume and it leaves a trail. In 2024, 25% of Medicare fee-for-service users had a telehealth service, and the workflow choices behind those encounters determine whether quality is legible or fuzzy. Separately, the AMA reports that 71.4% of physicians used telehealth in 2024, a sign that online care is not a side channel anymore. It is normal care.
Dr. Xie has consistently regarded the deep integration of online and offline channels as an issue that requires systematic research, rather than a simple assumption. As first corresponding author, she published a PubMed-indexed 2021 study on the characteristics of online health care services from China’s largest online medical platform, using observed service behavior to make quality discussable in concrete terms. That publication matters in this conversation because evidence-first operations start with the habit of measuring what really happened, not what the process document hoped would happen.
Evidence breaks most often at the handoff. A clinical plan sounds clear until it hits quality review. A quality requirement sounds simple until it hits a submission deadline. Nobody thinks they are introducing risk; they are just moving fast. This is where teams get hurt.
Xie’s work sits in the middle of those collisions. She collaborates with R&D, product team, quality assurance, regulatory affairs, and external partners, keeping the clinical story consistent while the work moves across functions. “The goal is not to win an argument in one meeting,” she says. “The goal is to keep the record consistent when five groups touch it.” That is how evidence stays intact when the pace picks up.
The next frontier is not only new markets, but new categories where the operating environment is less forgiving of fuzzy validation. Bioinoculants are a clean example because they force teams to apply disciplined proof outside the comfort of familiar clinical routines. You still need controlled methods. You still need traceability. You just cannot rely on legacy muscle memory.
That demand is showing up in the economics. The global biofertilizers market size was $1.38 billion in 2024 and is projected to reach $2.83 billion by 2030, a growth curve that favors teams who can prove performance and consistency rather than argue for it. Xie oversees clinical development for bioinoculants as part of Boston Easy Biotech’s broader portfolio, and her repeated SARC paper review roles matter here because they reflect a working comfort with scrutinizing methods, not just outcomes. “If we want trust at scale, we have to earn it with records,” notes Xie. “Confidence is not the deliverable, consistency is. When the market grows, the only argument that holds up is proof you can repeat.”